RFG Advisory’s Neurocrine Biosciences NBIX Stock Holding History

RFG Advisory’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-8,195	Closed	-$1.38M	–	1271
2026 Q2	$1.38M	Buy	+8,195	New	+$1.22M	0.02%	469

Other funds holding NBIX

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $61B AUM 26.91% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

IEQ Capital Foster City, California $23.5B AUM 29.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

GW&K Investment Management Boston, Massachusetts $11.8B AUM 29.45% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $45.5B AUM 15.2% 1-Year Est. Return

RFG Advisory's NBIX Position: Q3 2026 in Review

RFG Advisory sold out of Neurocrine Biosciences (NBIX) in Q3 2026, closing a stake of 8,195 shares — an estimated $1.38M sold.

RFG Advisory first reported a position in NBIX in Q2 2026 and held it in 1 quarter. The position peaked at $1.38M in Q2 2026. 446 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

RFG Advisory reported no remaining Neurocrine Biosciences position as of Q3 2026 after selling out during the quarter.
RFG Advisory sold 8,195 Neurocrine Biosciences shares in Q3 2026, an estimated $1.38M.
RFG Advisory first reported a position in Neurocrine Biosciences in Q2 2026 and held it in 1 quarter.
RFG Advisory's Neurocrine Biosciences position peaked at $1.38M in Q2 2026.
446 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on RFG Advisory's 13F filing for Q3 2026, filed 3 Nov 2026.